Evidence map›Paper›PMID 37095250›Full record

Trial reportNature medicine2023

Tau-targeting antisense oligonucleotide MAPT

Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph and 17 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06706947 (Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease), which is not on this map. Cited by 195 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 3 pooled it
51.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06706947 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease

TypeinterventionalSponsorLuo XinxinRan2024 to 2025Enrolled20ConditionsAlzheimer&amp, #39, s Disease (AD)ArmsLymphaticovenous Anastomosis
3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 3 syntheses or guidelines pooled it, 293 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Cross-disease protein aggregate interactions in neurodegeneration: from molecular mechanisms to therapeutic strategies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 13 institutions in 7 countries.

Catherine J MummeryDementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK. c.mummery@ucl.ac.uk.ORCID 0000-0002-6739-0803
Anne Börjesson-HansonKarolinska University Hospital, ME Aging, Stockholm, Sweden.
Daniel J BlackburnSheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.
Everard G B VijverbergAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Peter Paul De DeynUniversity Medical Center Groningen / RUG, Alzheimer Center Groningen, Groningen, the Netherlands.
Simon DucharmeDouglas Mental Health University Institute and McConnell Brain Imaging Centre of the Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-7309-1113
Michael JonssonMemory Clinic, Psychiatry - Cognition and Geriatric Psychiatry, Sahlgrenska University Hospital, Gothenburg/Molndal, Sweden.
Anja SchneiderGerman Center for Neurodegenerative Diseases, DZNE, and Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
Juha O RinneCRST Oy; Turku PET Centre University of Turku and Turku University Hospital, Turku, Finland.ORCID 0000-0001-6369-0764
Albert C LudolphDepartment of Neurology University of Ulm and DZNE, Ulm, Germany.
Ralf BodenschatzPharmakologisches Studienzentrum Chemnitz GmbH Mittweida, Mittweida, Germany.
Holly Kordasiewicz *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Eric E Swayze *Ionis Pharmaceuticals, Carlsbad, CA, USA.ORCID 0000-0001-6430-6576
Bethany Fitzsimmons *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Laurence Mignon *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Katrina M Moore *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Chris Yun *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Tiffany Baumann *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Dan Li *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Daniel A Norris *Ionis Pharmaceuticals, Carlsbad, CA, USA.ORCID 0000-0003-2074-5862
Rebecca Crean *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Danielle L Graham *Biogen, Cambridge, MA, USA.
Ellen Huang *Biogen, Cambridge, MA, USA.
Elena Ratti *Biogen, Cambridge, MA, USA.
C Frank Bennett *Ionis Pharmaceuticals, Carlsbad, CA, USA.
Candice JungeIonis Pharmaceuticals, Carlsbad, CA, USA.
Roger M LaneIonis Pharmaceuticals, Carlsbad, CA, USA.
Ionis Pharmaceuticals (United States) · USBiogen (United States) · USAmsterdam Neuroscience · NLDouglas Mental Health University Institute · CAHochschule Mittweida · DEKarolinska University Hospital · SERoyal Hallamshire Hospital · GBSahlgrenska University Hospital · SEUK Dementia Research Institute · GBUniversität Ulm · DEUniversity Hospital Bonn · DEUniversity Medical Center Groningen · NLUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPT

Indexed as

Alzheimer Diseasetau ProteinsDouble-Blind MethodHumansOligonucleotides, AntisenseTreatment OutcomeMAPT protein, humanOligonucleotides, Antisensetau Proteins

Identifiers

PMID37095250
PMCPMC10287562
OpenAlexW4366824059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.